Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Endocr Disord ; 22(1): 265, 2022 Nov 01.
Article in English | MEDLINE | ID: mdl-36316664

ABSTRACT

BACKGROUND: Ovarian steroid cell tumors (SCTs), not otherwise specified (NOS), are rare, with few large studies. The purpose of this study was to analyze the clinical features, prognosis, and treatment choices for these patients of different age groups. METHODS: This was a retrospective study. We identified nine cases of ovarian steroid cell tumor, not otherwise specified, confirmed by post-operative histopathological examination, and analyzed clinical features, surgical procedures, and follow up outcomes. We also reviewed cases reports of ovarian steroid cell tumors, not otherwise specified. RESULTS: A total of nine cases were included. The age range was 9-68 years (mean, 41.89 ± 19.72 years). Clinical features included virilization, amenorrhea, abdominal pain, vaginal bleeding, isosexual precocious puberty, Cushing's syndrome, and abnormal weight gain with elevated testosterone levels. The follow up interval ranged 5-53 months and no recurrence was observed. CONCLUSION: Ovarian steroid cell tumors covered all age groups, with manifestations of androgen excess. Younger patients appeared to have a more favorable prognosis, which provided more opportunities for these patients to pursue treatment options that will preserve reproductive function.


Subject(s)
Ovarian Neoplasms , Sex Cord-Gonadal Stromal Tumors , Female , Humans , Child , Adolescent , Young Adult , Adult , Middle Aged , Aged , Retrospective Studies , Sex Cord-Gonadal Stromal Tumors/pathology , Ovarian Neoplasms/pathology , Virilism , Steroids
2.
Int J Gynaecol Obstet ; 143(2): 172-177, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30074243

ABSTRACT

OBJECTIVE: To evaluate the efficacy and long-term prognosis of uterine artery chemoembolization (UACE) combined with curettage for treatment of cesarean scar pregnancy (CSP). METHODS: Data were retrospectively reviewed from women with CSPs treated by UACE with curettage at Women's Hospital of Zhejiang University, Hangzhou, a tertiary obstetrics and gynecologic center in China, between December 2006 and December 2016. Information on clinical characteristics and treatment outcomes was obtained from medical records and follow-up interviews. RESULTS: There were 383 patients included; 379 (99.0%) women were successfully treated. Risk factors associated with intraoperative bleeding were size of gestational mass (P=0.001), presence of fetal heart beat (P=0.002), and type of CSP (P=0.002). Among 301 women with complete medical records over a mean ± SD follow-up of 49.8 ± 30.2 months, 164 (54.5%) women resumed normal menstruation and only 22 (7.3%) experienced a reduction in menstrual volume of more than one-half. Among 89 women attempting to conceive, the conception rate was 69% (61/89), the positive pregnancy rate was 80% (49/61), and 35 live neonates were delivered. CONCLUSION: UACE combined with curettage was found to be an effective fertility-sparing treatment for CSP. Further, the approach did not seem to harm future reproductive ability.


Subject(s)
Chemoembolization, Therapeutic/statistics & numerical data , Cicatrix , Dilatation and Curettage/statistics & numerical data , Pregnancy, Ectopic/surgery , Uterine Artery Embolization/statistics & numerical data , Uterine Artery/surgery , Adult , Cesarean Section/adverse effects , Cesarean Section/statistics & numerical data , China , Female , Fertility Preservation/methods , Humans , Menstruation , Middle Aged , Pregnancy , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...